This Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides funding of $367,472 to Gynion, LLC to develop the Clarablex Gel, a novel chemical ablative therapy for the treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition that can lead to cervical cancer. The Clarablex Gel, which is formulated with trichloroacetic acid as the active ingredient, is designed to be a simple, effective, and affordable treatment that can be deployed at the point-of-care immediately after a patient is diagnosed with CIN. The Phase I study will focus on developing the cervical applicator, refining the gel formulation, and conducting ex vivo exposure studies to demonstrate the potential effectiveness of the treatment. The subsequent Phase II project will assess the toxicological and clinical safety of the Clarablex Gel.
Generated 1/28/25, 10:41 AM